151982-51-3

Basic information

• Product Name: 4-BROMO-2-FLUOROBENZOYL CHLORIDE
• Synonyms: 2-FLUORO-4-BROMOBENZOYL CHLORIDE;4-BROMO-2-FLUOROBENZOYL CHLORIDE;4-BROMO-2-FLUOROBENZOYL CHLORIDE 99%;4-Bromo-2-fluorobenzoyl chloride,99%;2-fluoro-4-broMobenzyl chloride;4-BroMo-2-fluorobenzoyl chloride, 99% 5GR;Benzoyl chloride, 4-broMo-2-fluoro-
• CAS NO: 151982-51-3
• Molecular Formula: C₇H₃BrClFO
• Molecular Weight: 237.45
• Product Categories: Fluorine series
• Mol File: 151982-51-3.mol

Chemical Properties

• Melting Point: 24-24.5 °C
• Boiling Point: 86-88 °C (15 mmHg)
• Flash Point: 86-88°C/15mm
• Appearance: White to light yellow/Liquid or Crystalline Mass
• Density: 1.743 g/cm³
• Vapor Pressure: 0.0462mmHg at 25°C
• Refractive Index: 1.5877
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Sensitive: Lachrymatory
• BRN: 6323925
• CAS DataBase Reference: 4-BROMO-2-FLUOROBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-FLUOROBENZOYL CHLORIDE(151982-51-3)
• EPA Substance Registry System: 4-BROMO-2-FLUOROBENZOYL CHLORIDE(151982-51-3)

Safety Data

• Hazard Codes: C,Xn
• Statements: 34-22
• Safety Statements: 45-36/37/39-26
• RIDADR: 3265
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 151982-51-3(Hazardous Substances Data)

Usage

Chemical Properties

white to light yellow liquid or crystalline mass

InChI:InChI=1/C7H3BrClFO/c8-4-1-2-5(7(9)11)6(10)3-4/h1-3H

Upstream product

• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Downstream Products

• 151982-61-5 4-(4-Bromo-2-fluoro-benzoyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 
• 151982-57-9 4-(4-Bromo-2-fluoro-benzoyl)-1H-pyrrole-2-carboxylic acid ethyl ester 
• 192443-10-0 (4-bromo-2-fluorophenyl)(4-methoxyphenyl)methanone 
• 695187-97-4 2-(2-fluoro-4-bromophenyl)benzoxazol-5-ylacetic acid methyl ester 
• 876611-26-6 (4-bromo-2-fluorophenyl)(4-phenoxyphenyl)methanone 
• 1000147-80-7 4-bromo-2-fluoro-N-[(2R)-2-hydroxypropyl]benzamide 
• 1016641-83-0 C₁₈H₁₀BrN₃O₂ 
• 876611-28-8 {2-fluoro-4-[(trimethylsilyl)ethynyl]phenyl}(4-phenoxyphenyl)methanone 
• 192443-62-2 4-(6-bromo-benzo[d]isothiazol-3-yl)-phenol 
• 147433-64-5 4-(4-Bromo-2-fluoro-benzyl)-1H-pyrrole-2-carboxylic acid 
• 147433-65-6 4-(4-Bromo-2-fluoro-benzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid 
• 151982-66-0 4-(4-Bromo-2-fluoro-benzyl)-1H-pyrrole-2-carboxylic acid ethyl ester 
• 151982-70-6 4-(4-Bromo-2-fluoro-benzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester 
• 147433-82-7 {[4-(4-Bromo-2-fluoro-benzyl)-1H-pyrrole-2-carbonyl]-amino}-acetic acid ethyl ester 

Relevant articles and documents

Discovery and characterization of N-(1,3-dialkyl-1H-indazol-6-yl)-1H-pyrazolo[4,3-b]pyridin-3-amine scaffold as mGlu4 positive allosteric modulators that mitigate CYP1A2 induction liability

Previous reports from our laboratory disclosed the structure and activity of a novel 1H-pyrazolo[4,3-b]pyridine-3-amine scaffold (VU8506) which showed excellent potency, selectivity and in vivo efficacy in preclinical rodent models of Parkinson's disease.

PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF

The present disclosure relates to compounds of Formula (I) and (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating H1 and 5-HT2A receptors and are to be used in the treatment of sleep disorders, such as sleep fragmentation, disturbed sleep/arousals, and arousal threshold.

Method for synthesizing high-purity tert-butyl 2-fluoro-4-bromobenzoate

The invention discloses a method for synthesizing high-purity tert-butyl 2-fluoro-4-bromobenzoate, which comprises the following steps: synthesizing a compound 2-fluorine-4-bromobenzoyl chloride from 2-fluorine-4-bromobenzoic acid, then synthesizing the t

Structure-activity relationships of agonists for the orphan G protein-coupled receptor GPR27

GPR27 belongs, with GPR85 and GPR173, to a small subfamily of three receptors called “Super-Conserved Receptors Expressed in the Brain” (SREB). It has been postulated to participate in key physiological processes such as neuronal plasticity, energy metabolism, and pancreatic β-cell insulin secretion and regulation. Recently, we reported the first selective GPR27 agonist, 2,4-dichloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (I, pEC50 6.34, Emax 100%). Here, we describe the synthesis and structure-activity relationships of a series of new derivatives and analogs of I. All products were evaluated for their ability to activate GPR27 in an arrestin recruitment assay. As a result, agonists were identified with a broad range of efficacies including partial and full agonists, showing higher efficacies than the lead compound I. The most potent agonist was 4-chloro-2,5-difluoro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7y, pEC50 6.85, Emax 37%), and the agonists with higher efficacies were 4-chloro-2-methyl-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7p, pEC50 6.04, Emax 123%), and 2-bromo-4-chloro-N-(4-(N-phenylsulfamoyl)phenyl)benzamide (7r, pEC50 5.99, Emax 123%). Docking studies predicted the putative binding site and interactions of agonist 7p with GPR27. Selected potent agonists were found to be soluble and devoid of cellular toxicity within the range of their pharmacological activity. Therefore, they represent important new tools to further characterize the (patho)physiological roles of GPR27.

CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND

Provided herein is a crystalline hydrate of the compound of formula 1: Also provides herein are pharmaceutical compositions comprising such crystalline hydrate, methods of using such crystalline hydrate to treat respiratory diseases, and processes useful

NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE

Pharmaceutical compositions of the invention comprise herteroaromatic compounds having a disease-modifying action in the treatment of fungal infections and diseases associated with fungal infection.

Hit-to-Lead Optimization of Benzoxazepinoindazoles As Human African Trypanosomiasis Therapeutics

Human African trypanosomiasis (HAT) is a neglected tropical disease caused by infection with either of two subspecies of the parasite Trypanosoma brucei. Due to a lack of economic incentive to develop new drugs, current treatments have severe limitations in terms of safety, efficacy, and ease of administration. In an effort to develop new HAT therapeutics, we report the structure-activity relationships around T. brucei for a series of benzoxazepinoindazoles previously identified through a high-throughput screen of human kinase inhibitors, and the subsequent in vivo experiments for HAT. We identified compound 18, which showed an improved kinase selectivity profile and acceptable pharmacokinetic parameters, as a promising lead. Although treatment with 18 cured 60% of mice in a systemic model of HAT, the compound was unable to clear parasitemia in a CNS model of the disease. We also report the results of cross-screening these compounds against T. cruzi, L. donovani, and S. mansoni.

PROCESS FOR PREPARING JAK INHIBITORS AND INTERMEDIATES THEREOF

The invention is directed to a process for preparing compounds which are useful as intermediates for the preparation of medicinal agents having inhibitory activity for JAK.

DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS

The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions compris

Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase

The cholinesterase enzymes play a vital role in maintaining balanced levels of the neurotransmitter acetylcholine in the central nervous system. However, the overexpression of these enzymes results in hampered neurotransmission. Both the major forms of cholinesterase enzymes viz. acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) play a crucial role in blocking neurotransmission; therefore, in recent years, a strategy of dual cholinesterase inhibition is being explored. Herein, we developed an energy-optimized e-pharmacophore hypothesis AHHPRR from AChE-donepezil complex and screened a set of 15 scaffolds that were designed imaginarily. The ligand with N-(1-benzylpyridinium) benzamide framework has shown the highest fitness and volume score, which was chosen for synthesis and validation. A series of pyridinium benzamides were synthesized and screened for cholinesterase inhibition that led to the identification of 7b, a naphthalene containing N-(1-benzylpiperidine) benzamide as a potent dual AChE and BChE inhibitor with IC50 values of 0.176, and 0.47 μM, respectively. The kinetic study indicated that 7b inhibits AChE in a non-competitive manner with Ki value of 0.21 μM, and BChE in a mixed-fashion with Ki of 0.15 μM. The observed mode of inhibition was corroborated with molecular docking studies. The MD simulation studies pointed out that both AChE and BChE undergo low conformational changes in complex with 7b. The benzamide 7b displayed high BBB permeability in PAMPA assay, which indicates its potential for further exploration in preclinical studies for Alzheimer's disease.